Literature DB >> 21894205

Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.

Sean H Lim, Peter W M Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21894205     DOI： 10.1038/nrclinonc.2011.137

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

Authors:  Peter W M Johnson; Matthew R Sydes; Barry W Hancock; Michael Cullen; John A Radford; Sally P Stenning
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

2.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Authors:  Simonetta Viviani; Pier Luigi Zinzani; Alessandro Rambaldi; Ercole Brusamolino; Alessandro Levis; Valeria Bonfante; Umberto Vitolo; Alessandro Pulsoni; Anna Marina Liberati; Giorgina Specchia; Pinuccia Valagussa; Andrea Rossi; Francesco Zaja; Enrico M Pogliani; Patrizia Pregno; Manuel Gotti; Andrea Gallamini; Delia Rota Scalabrini; Gianni Bonadonna; Alessandro M Gianni
Journal:  N Engl J Med       Date:  2011-07-21       Impact factor: 91.245

3.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Authors:  Andreas Engert; Volker Diehl; Jeremy Franklin; Andreas Lohri; Bernd Dörken; Wolf-Dieter Ludwig; Peter Koch; Mathias Hänel; Michael Pfreundschuh; Martin Wilhelm; Lorenz Trümper; Walter-Erich Aulitzky; Martin Bentz; Mathias Rummel; Orhan Sezer; Hans-Konrad Müller-Hermelink; Dirk Hasenclever; Markus Löffler
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

4.  Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

Authors:  Peter J Hoskin; Lisa Lowry; Alan Horwich; Andrew Jack; Ben Mead; Barry W Hancock; Paul Smith; Wendi Qian; Philippa Patrick; Bilyana Popova; Andrew Pettitt; David Cunningham; Ruth Pettengell; John Sweetenham; David Linch; Peter W M Johnson
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

5.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Authors:  Massimo Federico; Stefano Luminari; Emilio Iannitto; Giuseppe Polimeno; Luigi Marcheselli; Antonella Montanini; Antonio La Sala; Francesco Merli; Caterina Stelitano; Samantha Pozzi; Renato Scalone; Nicola Di Renzo; Pellegrino Musto; Luca Baldini; Giulia Cervetti; Francesco Angrilli; Patrizio Mazza; Maura Brugiatelli; Paolo G Gobbi
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

6.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

7.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

8.  Involved-field radiotherapy for advanced Hodgkin's lymphoma.

Authors:  Berthe M P Aleman; John M M Raemaekers; Umberto Tirelli; Roberto Bortolus; Mars B van 't Veer; Marnix L M Lybeert; Jo J Keuning; Patrice Carde; Théodore Girinsky; Richard W M van der Maazen; Radka Tomsic; Marjeta Vovk; Achilles van Hoof; Geertrui Demeestere; Pieternella J Lugtenburg; José Thomas; Wilfried Schroyens; Koenraad De Boeck; Johanna W Baars; Johanna C Kluin-Nelemans; Christian Carrie; Malek Aoudjhane; Dominique Bron; Houchingue Eghbali; Wilma G J M Smit; Jacobus H Meerwaldt; Anton Hagenbeek; Antonella Pinna; Michel Henry-Amar
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

9.  Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

Authors:  Peter W M Johnson; John A Radford; Michael H Cullen; Matthew R Sydes; Jan Walewski; Andrew S Jack; Kenneth A MacLennan; Sally P Stenning; Simon Clawson; Paul Smith; David Ryder; Barry W Hancock
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544
  9 in total
  1 in total

1.  Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Authors:  Anas Younes; Yasuhiro Oki; Peter McLaughlin; Amanda R Copeland; Andre Goy; Barbara Pro; Lei Feng; Ying Yuan; Hubert H Chuang; Homer A Macapinlac; Fredrick Hagemeister; Jorge Romaguera; Felipe Samaniego; Michelle A Fanale; Bouthaina Shbib Dabaja; Maria A Rodriguez; Nam Dang; Larry W Kwak; Sattva S Neelapu; Luis E Fayad
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.